{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:53:34Z","timestamp":1789019614016,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Methotrexate is an immunosuppressant and chemotherapeutic agent used in the treatment of a range of autoimmune disorders and cancers. Its main serious adverse effects, bone marrow suppression and gastrointestinal complications, arise from its antimetabolite effect. Nevertheless, hepatotoxicity and nephrotoxicity are two widely described adverse effects of methotrexate. Its hepatotoxicity has been studied mainly in the low-dose, chronic setting, where patients are at risk of fibrosis\/cirrhosis. Studies of acute hepatoxicity of high dose methotrexate, such as during chemotherapy, are scarce. We present the case of a 14-year-old patient who received high-dose methotrexate and subsequently developed acute fulminant liver failure and acute kidney injury. Genotyping of <jats:italic>MTHFR<\/jats:italic> (Methylene tetrahydrofolate reductase gene), <jats:italic>ABCB1<\/jats:italic> (codes for P-glycoprotein, intestinal transport and biliary excretion), <jats:italic>ABCG2<\/jats:italic> (codes for BCRP, intestinal transporter and renal excretion) and <jats:italic>SLCO1B1<\/jats:italic> (codes for OATP1B1, hepatic transporter) identified variants in all the genes analysed that predicted a reduced rate of methotrexate elimination and thus may have contributed to the clinical situation of the patient. Precision medicine involving pharmacogenomic testing could potentially avoid such adverse drug effects.<\/jats:p>","DOI":"10.3389\/fphar.2023.1130548","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T04:48:46Z","timestamp":1683002926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023?"],"prefix":"10.3389","volume":"14","author":[{"given":"Ali El Rida","family":"El Masri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Tobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breunis","family":"Willemijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre O.","family":"Von Bueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Flora","family":"Samer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0305-7372(77)80007-8","article-title":"Methotrexate: Clinical pharmacology, current status and therapeutic guidelines","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat. Rev."},{"key":"B2","first-page":"36","article-title":"Glucarpidase treatment for methotrexate intoxication: A case report and review of the literature","volume":"76","author":"Boelens","year":"2018","journal-title":"Neth J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","article-title":"Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/jpm10040149","article-title":"Clinical and laboratory associations with methotrexate metabolism gene polymorphisms in rheumatoid arthritis","volume":"10","author":"D\u2019Cruz","year":"2020","journal-title":"J. Pers. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/sj.tpj.6500480","article-title":"Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy","volume":"8","author":"Erdilyi","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","article-title":"PharmGKB summary: Very important pharmacogene information for ABCG2","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2217\/pgs.13.13","article-title":"Pharmacogenetics of opiates in clinical practice: The visible tip of the iceberg","volume":"14","author":"Hajj","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","article-title":"High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients","volume":"73","author":"Holmboe","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia: SLCO1B1 polymorphisms and MTX toxicity in ALL","volume":"57","author":"Lopez-Lopez","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: Methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FPC.0b013e328333b99c","article-title":"PharmGKB very important pharmacogene: SLCO1B1","volume":"20","author":"Oshiro","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin. Nephrol."},{"key":"B15","volume-title":"23. PharmGKB, ABCB1 VI pharmacogene","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/BF00686272","article-title":"Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma","volume":"33","author":"Pignon","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-6606-6-8","article-title":"Combined analysis of circulating beta-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects","volume":"6","author":"Rhodin","year":"2013","journal-title":"Mol. Brain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/cncr.23292","article-title":"Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2217\/pgs.12.152","article-title":"Pharmacogenomics of opioids and perioperative pain management","volume":"13","author":"Sadhasivam","year":"2012","journal-title":"Pharmacogenomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"757464","DOI":"10.3389\/fphar.2021.757464","article-title":"The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: A systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/FPC.0b013e3283398a71","article-title":"Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate","volume":"20","author":"Stamp","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B25","unstructured":"Information provided by the manufacturerSwiss Drug Regulator"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevi\u00f1o","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","article-title":"The antifolates","volume":"26","author":"Visentin","year":"2012","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B29","first-page":"5538","article-title":"Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter","volume":"63","author":"Volk","year":"2003","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","article-title":"Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: A meta-analysis","volume":"33","author":"Yang","year":"2012","journal-title":"Tumour Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/ph14101036","article-title":"Folium sennae increased the bioavailability of methotrexate through modulation on MRP 2 and BCRP","volume":"14","author":"Yu","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13318-021-00737-6","article-title":"A systematic review of population pharmacokinetic models of methotrexate","volume":"47","author":"Zhang","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","article-title":"Mechanisms of membrane transport of folates into cells and across epithelia","volume":"31","author":"Zhao","year":"2011","journal-title":"Annu. Rev. Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1130548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T04:48:53Z","timestamp":1683002933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1130548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":33,"alternative-id":["10.3389\/fphar.2023.1130548"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1130548","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"article-number":"1130548"}}